FIGURE 2.

Investigator‐assessed PFS according to best response to last platinum‐based chemotherapy. Patients with a CR to last platinum‐based chemotherapy in the (A) BRCA‐mutated cohort, (B) HRD cohort, and (C) ITT population. Patients with a PR to last platinum‐based chemotherapy in the (D) BRCA‐mutated cohort, (E) HRD cohort, and (F) ITT population. p values were nonsignificant for treatment by best response subgroup (CR vs. PR) interaction tests (BRCA‐mutated cohort, p = 0.5680; HRD cohort, p = 0.4029; ITT population, p = 0.7001). P values are presented for descriptive purposes only. CI indicates confidence interval; CR, complete response; HR, hazard ratio; HRD, homologous recombination deficient; ITT, intent to treat; NR, not reached; PFS, progression‐free survival; PR, partial response